Skip to main content
. 2022 Jun 30;14(13):3206. doi: 10.3390/cancers14133206

Table 2.

Comparison of patient and tumor characteristics between various subgroups of lung cancer patients, P-L, L and L-P.

Covariate Level P-L
N = 11,061
L-P
N = 3017
L
N = 353,672
Parametric p-Value *
Age at Diagnosis of Lung Cancer <65 years 571 (5.16) 817 (27.08) 55,459 (15.68) <0.001
≥65 years 10,490 (94.84) 2200 (72.92) 298,213 (84.32)
Age at Diagnosis of Prostate Cancer <65 years 1971 (17.82) 437 (14.48) <0.001
≥65 years 9090 (82.18) 2580 (85.52)
Race White 8879 (80.78) 2380 (79.31) 296,084 (84.34) <0.001
Black 1502 (13.67) 461 (15.36) 31,919 (9.09)
Other 241 (2.19) 76 (2.53) 11,715 (3.34)
Asian 242 (2.2) 60 (2) 7943 (2.26)
Hispanic 127 (1.16) 24 (0.8) 3389 (0.97)
Histologic Subtypes of Lung Cancer NSCLC 8582 (77.6) 2656 (88.0) 263,758 (74.6)
SCLC 250 (2.3) 36 (1.2) 11,821 (3.3)
Carcinoma In Situ and
Other Histologies
2229 (20.2) 325 (10.8) 78,093 (22.1)
Distribution by Stage of Lung Cancer at Diagnosis I 1382 (19.8) 824 (54.1)
II 199 (2.9) 99 (6.5)
III 2386 (34.2) 323 (21.2)
IV 3009 (43.1) 277 (18.2)

L: Lung Cancer without Prostate Cancer; L-P: Lung Cancer followed by Prostate Cancer; P-L: Prostate Cancer followed by Lung Cancer; NSCLC: Non-Small Cell Lung Cancer; SCLC: Small Cell Lung Cancer. * p < 0.001